MaxCyte third-quarter 2026 revenue hit $10.2 million, up 49%
Por Liezl GambePontos principais
- MaxCyte reported third-quarter 2026 revenue of $10.2 million, up 49% year-over-year, including $8.2 million in core revenue.
- Net loss narrowed to $4.8 million from $12.4 million, while gross margin increased to 83% from 77%.
- MaxCyte raised its 2026 revenue forecast to at least $34.5 million, excluding the proposed Akron Bio acquisition.
MaxCyte (NASDAQ:MXCT) raised its full-year 2026 revenue guidance to at least $34.5 million after reporting third-quarter revenue of $10.2 million, up 49% year-over-year.
Core revenue contributed $8.2 million, while Strategic Platform License programs generated another $2 million during the quarter.
Net loss narrowed to $4.8 million from $12.4 million a year earlier, while gross margin increased to 83% from 77%.
The revised revenue forecast includes approximately $28 million in core revenue and excludes the proposed Akron Bio acquisition, while the company expects second-half core revenue growth of approximately 15% year-over-year.
Assuming the Akron Bio acquisition closes, MaxCyte expects year-end cash, cash equivalents and investments of approximately $40 million–$45 million, compared with $132.7 million at September 30, accounting for approximately $105 million in cash payments and acquisition expenses alongside a $22 million draw under its MidCap Financial credit facility.
The company continues to develop its cell-engineering technology platform through core commercial operations and Strategic Platform License partnerships, while the proposed Akron Bio acquisition remains subject to completion.
